Doriano Fabbro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Doriano Fabbro has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- David Shugar
Institute of Biochemistry and Biophysics PAS, Pawińskiego 5a, 02-106 Warszawa, Poland
2 shared publications - Denise Rageot
Department of Biomedicine, University of Basel, Mattenstrasse 28, Basel, 4056, Switzerland
2 shared publications - Matthias P. Wymann
Department of Biomedicine, University of Basel, Basel, Switzerland
2 shared publications - Petra Hillmann
PIQUR Therapeutics AG, Hochbergerstrasse 60C, Basel, 4057, Switzerland
2 shared publications - Anastasios Stathis
Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland
1 shared publication - Carolin Walter
Institute of Medical Genetics and Applied Genomics, University of Tuebingen, Calwerstrasse 7, Tuebingen, 72076, Germany; Centre for Rare Diseases (ZSE), University of Tuebingen, Calwerstrasse 7, Tuebingen, 72076, Germany
1 shared publication
Latest Publications
- 1 January 2020
- Published by Elsevier in Neuropharmacology
- Vol. 162, 107812
Brain-penetrant PQR620 mTOR and PQR530 PI3K/mTOR inhibitor reduce huntingtin levels in cell models of HD
- 1 January 2020
- Published by Elsevier in Neuropharmacology
- Vol. 162, 107812
Brain-penetrant PQR620 mTOR and PQR530 PI3K/mTOR inhibitor reduce huntingtin levels in cell models of HD
- Open Access
The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax
The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling cascade is an important therapeutic target for lymphomas. Rapamycin-derivates as allosteric mTOR complex 1 (TORC1) inhibitors have shown moderate preclinical and clinical anti-lymphoma activity. Here, we assessed the anti-tumor activity of PQR620, a novel brain penetrant dual TORC1/2 inhibitor, in 56 lymphoma cell lines. We observed anti-tumor activity across 56 lymphoma models with a median IC50 value of 250 nM after 72 h of exposure. PQR620 was largely cytostatic, but the combination with the BCL2 inhibitor venetoclax led to cytotoxicity. Both the single agent and the combination data were validated in xenograft models. The data support further evaluation of PQR620 as a single agent or in combination with venetoclax.
Open AccessThe Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax
The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling cascade is an important therapeutic target for lymphomas. Rapamycin-derivates as allosteric mTOR complex 1 (TORC1) inhibitors have shown moderate preclinical and clinical anti-lymphoma activity. Here, we assessed the anti-tumor activity of PQR620, a novel brain penetrant dual TORC1/2 inhibitor, in 56 lymphoma cell lines. We observed anti-tumor activity across 56 lymphoma models with a median IC50 value of 250 nM after 72 h of exposure. PQR620 was largely cytostatic, but the combination with the BCL2 inhibitor venetoclax led to cytotoxicity. Both the single agent and the combination data were validated in xenograft models. The data support further evaluation of PQR620 as a single agent or in combination with venetoclax.
- 1 October 2015
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
- Vol. 1854 (10) , 1553-1554
8th International Conference on Inhibitors of Protein Kinases (IPK ’2014)
- 1 October 2015
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
- Vol. 1854 (10) , 1553-1554
8th International Conference on Inhibitors of Protein Kinases (IPK ’2014)
- Open Access
- 1 May 2015
- Published by Elsevier in Molecular Pharmacology
- Vol. 87 (5) , 766-775
25 Years of Small Molecular Weight Kinase Inhibitors: Potentials and Limitations
Deregulation of protein and lipid kinases of these kinase activities lead to a variety of pathologies ranging from cancer to inflammatory diseases, diabetes, infectious diseases, cardiovascular disorders, cell growth and survival. Protein kinase and lipid kinases represent, therefore, an important target for the pharmaceutical industry. In fact, approximately one third of all protein targets under investigation in the pharmaceutical industry are protein or lipid kinases. To date 27 kinase inhibitors that have been approved, which, with few exceptions, are mainly for oncological indications and are directed against only a handful of protein and lipid kinases, leaving 70% of the kinome untapped. Despite of these successes the major challenges in kinase drug discovery the development of kinase inhibitors with outstanding selectivity, the identification and validation of driver kinase(s) in diseases and the emerging resistance to the inhibition of key target kinases remain major challenges. This review will provide an insight into protein and lipid kinase drug discovery with respect to achievements, binding modes of inhibitors and novel avenues for the generation of second generation kinase inhibitors to treat cancers.
- 1 May 2015
- Published by Elsevier in Molecular Pharmacology
- Vol. 87 (5) , 766-775
Open Access25 Years of Small Molecular Weight Kinase Inhibitors: Potentials and Limitations
Deregulation of protein and lipid kinases of these kinase activities lead to a variety of pathologies ranging from cancer to inflammatory diseases, diabetes, infectious diseases, cardiovascular disorders, cell growth and survival. Protein kinase and lipid kinases represent, therefore, an important target for the pharmaceutical industry. In fact, approximately one third of all protein targets under investigation in the pharmaceutical industry are protein or lipid kinases. To date 27 kinase inhibitors that have been approved, which, with few exceptions, are mainly for oncological indications and are directed against only a handful of protein and lipid kinases, leaving 70% of the kinome untapped. Despite of these successes the major challenges in kinase drug discovery the development of kinase inhibitors with outstanding selectivity, the identification and validation of driver kinase(s) in diseases and the emerging resistance to the inhibition of key target kinases remain major challenges. This review will provide an insight into protein and lipid kinase drug discovery with respect to achievements, binding modes of inhibitors and novel avenues for the generation of second generation kinase inhibitors to treat cancers.
- 24 March 2015
- Published by Wiley in British Journal of Pharmacology
- Vol. 172 (11) , 2675-2700
Ten things you should know about protein kinases:IUPHAR Review 14
Many human malignancies are associated with aberrant regulation of protein or lipid kinases due to mutations, chromosomal rearrangements and/or gene amplification. Protein and lipid kinases represent an important target class for treating human disorders. This review focus on ‘the 10 things you should know about protein kinases and their inhibitors', including a short introduction on the history of protein kinases and their inhibitors and ending with a perspective on kinase drug discovery. Although the ‘10 things’ have been, to a certain extent, chosen arbitrarily, they cover in a comprehensive way the past and present efforts in kinase drug discovery and summarize thestatus quoof the current kinase inhibitors as well as knowledge about kinase structure and binding modes. Besides describing the potentials of protein kinase inhibitors as drugs, this review also focus on their limitations, particularly on how to circumvent emerging resistance against kinase inhibitors in oncological indications.
- 24 March 2015
- Published by Wiley in British Journal of Pharmacology
- Vol. 172 (11) , 2675-2700
Ten things you should know about protein kinases:IUPHAR Review 14
Many human malignancies are associated with aberrant regulation of protein or lipid kinases due to mutations, chromosomal rearrangements and/or gene amplification. Protein and lipid kinases represent an important target class for treating human disorders. This review focus on ‘the 10 things you should know about protein kinases and their inhibitors', including a short introduction on the history of protein kinases and their inhibitors and ending with a perspective on kinase drug discovery. Although the ‘10 things’ have been, to a certain extent, chosen arbitrarily, they cover in a comprehensive way the past and present efforts in kinase drug discovery and summarize thestatus quoof the current kinase inhibitors as well as knowledge about kinase structure and binding modes. Besides describing the potentials of protein kinase inhibitors as drugs, this review also focus on their limitations, particularly on how to circumvent emerging resistance against kinase inhibitors in oncological indications.
- 1 July 2013
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
- Vol. 1834 (7) , 1269-1270
Inhibitors of protein kinases
- 1 July 2013
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
- Vol. 1834 (7) , 1269-1270
Inhibitors of protein kinases